Asthma and COPD Drugs Market Highlights
The Asthma and COPD Drugs Market is projected to reach USD 34,374.23 Million by 2030 at 4.20% CAGR during the forecast period 2022-2030. Asthma is a type of inflammatory disease that affects the lungs and makes breathing difficult. It is one of the common chronic conditions affecting many people across the globe. COPD or chronic obstructive pulmonary disease is an umbrella term used for a group of respiratory diseases such as emphysema and chronic bronchitis.
Regional Analysis
Global asthma and COPD drugs market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas are likely to dominate global asthma and COPD drugs market. This can be attributed to the rising patient population suffering from asthma and COPD in the region. According to the American Academy of Allergy Asthma & Immunology, in 2016, approximately 8.3% of children in the US had asthma. Moreover, the rising health expenditure per person and increasing demand for advanced treatment options are also expected to drive market growth.
The European market for asthma and COPD drugs is expected to be the second largest during the review period. The growing awareness of asthma and COPD in Europe is expected to boost the growth of the regional market. For instance, in April 2017, the “United Action for Allergy and Asthma” was launched in Europe to raise awareness regarding asthma in the continent. Additionally, the prevalence of asthma and COPD is also increasing in Europe, which is also fuelling market growth.
Asia-Pacific is estimated to be the fastest-growing market owing to the rising awareness regarding COPD and asthma in the region. For instance, Koninklijke Philips launched a campaign in May 2019, for raising awareness of asthma in India on World Asthma Day. Moreover, a high prevalence of asthma and COPD is also positively affecting the market growth.
The market in the Middle East & Africa is expected to witness steady growth due to the rising patient population suffering from asthma and COPD in the Middle Eastern countries.
Segment Analysis
The Global Asthma and COPD Drugs Market have been segmented by disease, product, route of administration, and distribution channel. The market, based on disease, has been bifurcated into asthma and COPD.
Based on product, asthma and COPD drugs market has been segregated into long-term asthma control medications and quick-relief medications. The long-term asthma control medications are further segmented into combination drugs, anticholinergics, inhaled corticosteroids, long-acting beta-agonists, theophylline, and others. The combination drugs are further segregated into Seretide/Advair, Symbicort, Relvar/Breo Ellipta, Flutiform, Dulera, and others. Anticholinergics is further sub-segmented into Spiriva and others. Inhaled corticosteroids are further segmented into Pulmicort, Flovent, Qvar, and others.
The quick-relief medications have been further segmented into short-acting beta-agonists, oral & intravenous corticosteroids, ipratropium bromide (Atrovent), and others. Short-acting beta-agonists have been further segregated into Proair and Ventolin.
Global asthma and COPD drugs market, based on the route of administration, has been segmented into oral, inhaled, and others. Based on the distribution channels, global asthma and COPD drugs market report has been segmented into retail pharmacies, hospital pharmacies, and online pharmacies.
Key Players
The Global Asthma and COPD Drugs Market Players - GlaxoSmithKline plc (UK), AstraZeneca (UK), Boehringer Ingelheim International GmbH (Germany), and Chiesi Farmaceutici SpA (Italy).
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 628 258 0071
Email: [email protected]
Global Asthma and COPD Drugs Market: Information by Disease (COPD and Asthma), Product (Long-Term Asthma Control Medications, Quick Relief Medications), Route of Administration (Oral, Inhaled), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies) and Region (Americas, Europe, Asia-Pacific, Middle East & Africa) - Forecast till 2027Market HighlightsGlobal Asthma and COPD Drugs Market are expected to register a CAGR of 7.90% during the forecast period with a market value of USD 43,444.72 Million till 2025.
COPD or chronic obstructive pulmonary disease is an umbrella term used for a group of respiratory diseases such as emphysema and chronic bronchitis.Segment AnalysisThe Global Asthma and COPD Drugs Market have been segmented by disease, product, route of administration, and distribution channel.
Anticholinergics is further sub-segmented into Spiriva and others.
On the basis of the distribution channels, global asthma and COPD drugs market has been segmented into retail pharmacies, hospital pharmacies, and online pharmacies.Request Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/8749Regional AnalysisGlobal asthma and COPD drugs market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.The Americas are likely to dominate global asthma and COPD drugs market.
According to the American Academy of Allergy Asthma & Immunology, in 2016, approximately 8.3% of children in the US had asthma.
Moreover, the rising health expenditure per person and increasing demand for advanced treatment options are also expected to drive market growth.The European market for asthma and COPD drugs is expected to be the second-largest during the review period.
According to Market Research Future (MRFR), the global market for asthma and COPD drugs is projected to cross USD 43,444.72 million at a CAGR of 7.90% by 2025.
Asthma is one of the common chronic conditions that affect many people around the world.
COPD or chronic obstructive pulmonary disease is the umbrella term used in a category of respiratory disorders such as emphysema and chronic bronchitis.
Asthma and COPD Drugs Market SegmentationGlobal asthma and COPD drugs market has been segmented by disease, medication, route of administration, and distribution channels.The disease-based sector has been divided into asthma and COPD.Based on the product, asthma and COPD drugs market, drugs have been divided into long-term asthma control drugs and quick-relief drugs.
Across the basis of distribution networks, the global demand for asthma and COPD medicines has been segmented into specialty pharmacies, hospital pharmacies, and online pharmacies.
Asthma and COPD Drugs Market Regional AnalysisBased on the region, global asthma and COPD drugs market has been divided into the Americas, Europe, Asia Pacific, and the Middle East and Africa.The Americas are expected to dominate the global market for asthma and COPD medicines.
